Clinical Research Directory

Inclusion Criteria: 1. Age ≥18 years and ≤75 years, gender is not limited; 2. Patients with previously untreated, unruptured stable VBDAs clearly diagnosed by DSA, CTA or MRA; 3. Patients with aneurysm wall enhancement as shown by HR-VWI of 3.0T high field strength MRI whole body scanner at Tsinghua University; 4. Baseline mRS score ≤2; 5. Patients voluntarily participated in this study and signed an informed consent form. Exclusion Criteria: 1. Patients with aneurysms located in non-vertebral basilar artery sites (mainly referring to bifurcation saccular aneurysms); 2. Patients with combined diabetes or its complications; 3. Patients who are allergic to any components in MET; 4. Pregnant and lactating female patients; 5. Patients with other immune diseases in combination, patients taking immunosuppressants or anti-inflammatory drugs (such as long-term use of aspirin, statin, hormones and other drugs); 6. Target aneurysm-related symptoms were severe at the time of diagnosis, and the mRS score was ≥3; 7. VBDAs have received interventional or surgical treatment; 8. Those with severe allergy to the contrast agent gadolinium terlumate glucosamine (Gd-DTPA) (skin rash not counted); 9. Those with severe renal disease resulting in renal insufficiency (glomerular filtration rate \<30ml/(min·1.73m2)); 10. Patients with metal implants in the body (e.g., cardiac stents, cardiac prosthetic valves, pacemakers, metal joints, steel plates, non-removable metal dentures, etc.); 11. Patients known to suffer from dementia or psychiatric disorders and claustrophobia who are unable to complete the magnetic resonance examination; 12. Patients with other serious diseases combined at the time of diagnosis and with an expected survival time of less than 1 year; 13. Patients who are participating in clinical trials of other drugs or devices. 14. Other conditions judged by the investigator to exist that are unsuitable for enrollment.